Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | SOD1 | P00441 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14439401 | 0.89 | CYP3A4 (0.50) | CYP3A4LMNAACHEMEN1KMT2A | |
| SCHEMBL11435725 | 0.87 | CYP3A4 (0.62) | CYP3A4LMNAACHEMEN1KMT2A | |
| SCHEMBL10389716 | 0.86 | CYP3A4 (0.47) | CYP3A4LMNAACHEMEN1KMT2A | |
| SCHEMBL11424027 | 0.84 | CYP3A4 (0.59) | CYP3A4LMNAACHEMEN1KMT2A | |
| SCHEMBL13111819 | 0.84 | CYP3A4 (0.59) | CYP3A4LMNAACHEMEN1KMT2A | |
| SCHEMBL80101 | 0.84 | MEN1 (0.66) | CYP3A4LMNAACHEMEN1KMT2A | |
| SCHEMBL5838099 | 0.84 | TRPV1 (0.47) | CYP3A4LMNAACHEMEN1KMT2A | |
| SCHEMBL18697297 | 0.84 | ACHE (0.49) | CYP3A4LMNAACHEMEN1KMT2A | |
| SCHEMBL869141 | 0.84 | CYP3A4 (0.58) | CYP3A4LMNAACHE | |
| SCHEMBL13526085 | 0.83 | CYP3A4 (0.57) | CYP3A4LMNAACHEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | MEDICONNS SHANGHAI BIOPHARMACEUTICAL CO LTD (CN) | 2021-01-28 | — | — | US | disclosed |
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2020-08-18 | — | — | US | disclosed |
| EP-2249426-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEM CORP (JP) | 2019-07-10 | — | — | EP | disclosed |
| WO-2019053277-A1 | NURSERY FRUIT TREE OF AT LEAST DOUBLE TRUNK TYPE | GRADILIS RECHERCHE SARL (FR) | 2019-03-21 | — | — | WO | disclosed |
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2019-01-24 | — | — | US | disclosed |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | disclosed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110123871-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMCIAL (JP) | 2011-05-26 | — | — | US | disclosed |
| CN-101960662-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2011-01-26 | — | — | CN | disclosed |
| EP-2249426-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20090118417-A1 | Dendritic Polymer, Method for Producing the Same, and Thermoplastic Resin Composition | TORAY INDUSTRIES, INC. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-2003158-A9 | DENDRITIC POLYESTER, METHOD FOR PRODUCING THE SAME, AND THERMOPLASTIC RESIN COMPOSITION | TORAY INDUSTRIES, INC. (JP) | 2009-05-06 | — | — | EP | disclosed |
| CN-101415748-A | Dendritic polyester, method for producing the same, and thermoplastic resin composition | TORAY INDUSTRIES (JP) | 2009-04-22 | — | — | CN | disclosed |
| EP-2003158-A2 | DENDRITIC POLYESTER, METHOD FOR PRODUCING THE SAME, AND THERMOPLASTIC RESIN COMPOSITION | TORAY INDUSTRIES, INC. (JP) | 2008-12-17 | — | — | EP | disclosed |
| US-4777250-A | LOW MOLECULAR WEIGHT; STABLE | NORTHWESTERN UNIVERSITY (US) | 1988-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | CYP3A4 1260/4885LMNA 1834/4885ACHE 2066/4885 |
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | CYP3A4 1053/4885LMNA 2448/4885ACHE 4046/4885 |
| US-10030006-B2 | Coumarin based Hsp90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | CYP3A4 988/4885LMNA 2398/4885ACHE 4046/4885 |
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | PRLHR, DRD2, AVPR2 | CYP3A4 542/4885LMNA 4782/4885ACHE 597/4885 |
| US-10202322-B2 | Resorcinol derivatives | CNR1, CNR2, RCOR1 | CYP3A4 336/4885LMNA 3370/4885ACHE 1383/4885 |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | CNR1, CNR2, RCOR1 | CYP3A4 336/4885LMNA 3370/4885ACHE 1383/4885 |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | CYP3A4 988/4885LMNA 2398/4885ACHE 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.